Update on antiretroviral therapy

Archives of Disease in Childhood

Volumn 94, Issue 1, 2009, Pages 70-74

  Riordan, A ^a   Bugembe, T ^a  

^a ALDER HEY CHILDREN'S NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ATAZANAVIR; DARUNAVIR; DIDANOSINE; EFAVIRENZ; FLUTICASONE; NELFINAVIR; NEVIRAPINE; RITONAVIR; TENOFOVIR; TIPRANAVIR; ZIDOVUDINE;

ADRENAL SUPPRESSION; CD4 LYMPHOCYTE COUNT; CONGENITAL MALFORMATION; CUSHING SYNDROME; DIARRHEA; DIZZINESS; HALLUCINATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY REACTION; INFECTION PREVENTION; KIDNEY DISEASE; KIDNEY DYSFUNCTION; LIVER TOXICITY; LOW DRUG DOSE; MONOTHERAPY; MORBIDITY; MORTALITY; PANCREATITIS; PATIENT COMPLIANCE; PHARMACOGENETICS; PRIORITY JOURNAL; PSYCHOSIS; RASH; REVIEW; SIDE EFFECT; STEVENS JOHNSON SYNDROME; TOXICITY; VIRUS INFECTION;

ANTI-RETROVIRAL AGENTS; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MALE; PATIENT COMPLIANCE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; REVERSE TRANSCRIPTASE INHIBITORS; VIRAL LOAD;

EID: 58349113171     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.2007.128744     Document Type: Review

References (49)

1. Sharland M, Gibb DM, Tudor-Williams G. Advances in the prevention and treatment of paediatric HIV infection in the UK. Arch Dis Child 2002; 87:178-80.
2. Tookey P. HIV infection in childhood. In: BPSU 21st Annual Report 2006-7. London: British Paediatric Surveillance Unit, 2007:27-31.
3. Brugha R. Antiretroviral treatment in developing countries: the peril of neglecting private providers. BMJ 2003; 326:1382-4.
4. Weller IVD, Williams IG. ABC of AIDS: antiretroviral drugs. BMJ 2001; 322:1410-32.
5. World Health Organization. WHO antiretroviral therapy for infants and children 2008. Report of the WHO Technical Reference Group, Paediatric HIV/ART Care Guideline Group Meeting Geneva 2008. See http://www.who.int/hiv/ pub/paediatric/WHO-Paediatric-ART-guideline-rev-mreport-2008.pdf (accessed 29 October 2008).
6. Goetghebuer T, Haelterman E, Le Chenadec J, et al. Early vs deferred highly active antiretroviral therapy in HIV infected infants: a European Collaborative Cohort Study. Retrovirology 2008; 5(Suppl 1):025.
7. Violari A, Cotton M, Gibb D. Antiretroviral therapy initiated before 12 weeks of age reduces mortality in young HIV infected infants: evidence from the Children with HIV Early Antiretroviral Therapy (CHER) study. Abstract WESS103. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, Australia, 22-25 July 2007.
8. Welch SB. Gibb D. When should children with HIV infection be started on antiretroviral therapy? PLoS Med 2008; 5:e73.
9. Judd A, Doerholt K, Tookey PA, et al. Morbidity, mortality, and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996-2006: planning for teenage and adult care. Clin Infect Dis 2007; 45:918-24.
10. HIV Paediatric Prognostic Markers Collaboration Study Group. Short-term risk of disease progression in HIV-1-infected infants receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis. Lancet 2003; 362:1605-11.
11. Gortmaker SL, Hughes M, Cervia J, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med 2001; 345:1522-8.
12. Gibb DM, Duong T, Tookey PA, et al. Decline in mortality, AIDS and hospital admissions in perinatally HIV-1 infected children in the UK and Ireland. BMJ 2003; 327:1019-23.
13. Resino S, Resino R, Maria Bellon J, et al. Clinical outcomes improve with highly active antiretroviral therapy in vertically HIV type-1-infected children. Clin Infect Dis 2006; 43:243-52.
14. The European Collaborative Study. Natural history of vertically acquired human immunodeficiency virus-1 infection. Pediatrics 1994; 94:815-19.
15. Foster C, Lyall HEG. Children with HIV: improved mortality and morbidity with combination antiretroviral therapy. Curr Opin Infect Dis 2005; 18:253-9.
16. Reddi A, Leeper SC, Groebler A, et al. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal South Africa, BMC Pediatr 2007: 7:13.
17. Resino S, Bejlon JM, Sanchez-Ramon S, et al. Impact of antiretroviral protocols on dynamics of AIDS progression markers. Arch Dis Child 2002: 86:119-24.
18. Brogly S, Williams P, Seage GR. Antiretroviral treatment in paediatric HIV infection in the United States: from clinical trials to clinical practice. JAMA 2005; 293:2213-19.
19. Puthanakit T, Aurpibul L, Oberdofer P. Hospitalization and mortality among HIV infected children after receiving highly active antiretroviral therapy. Clin Infect Dis 2007; 44:599-64.
20. Sharland M, Blanche S, Castelli G, et al. PENTA guidelines for the use of antiretroviral therapy 2004. HIV Med 2004; 5(Suppl 2):61-86.
21. Tudor-Williams G, Head S, Weigel R, et al. Baby cocktail! A protease-sparing 4 drug combination for symptomatic infants. Abstract MoOrB1129. International Conference on AIDS, London, UK, 7-12 July 2002.
22. Walker AS, Doerholt K, Sharland M, et al. Response to highly active antiretroviral therapy varies with age: The UK and Ireland Collaborative HIV Paediatric Study. AIDS 2004; 18:1915-24.
23. Menson EN, Walker SA, Sharland M, et al. Underdosing of antiretrovirals in UK and Irish children with HIV as an example of problems in prescribing medicines to children 1997-2005: a cohort study. BMJ 2006; 332:1183-7.
24. Ellis JC, L'homme RF, Ewings FM, et al. Nevirapine concentrations in HIV-infected children treated with divided fixed-dose combination antiretroviral tablets in Malawi and Zambia. Antivir Ther 2007; 12:253-60.
25. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133:21-30.
26. Farley J, Hines S, Musk A. Assessment of adherence to antiviral therapy in HIV- infected children using the medication Evenet monitoring system, pharmacy refill, provider assessment, care-giver self report, and appointment keeping. J Acquir Immune Defic Syndr 2003; 33:211-18.
27. Lallemant M, Burger D, Lyall H, et al. Pharmacokinetic and virological evaluations after stopping NNRTIs in children: a substudy of the PENTA 11 (TICCH) trial. Abstract MOPE026. XVI International AIDS Conference, Toronto. Canada. 13-18 August 2006.
28. El-Sadr W, Neaton J. Episodic CD4-guided use of ART is inferior to continuous therapy: results of the SMART study. Abstract 106LB. 13th Conference on Retroviruses and Opportunistic Infections, Denver, USA, 5-8 February 2006.
29. Chakraborty R, Smith CJ, Dunn D, et al. HIV-1 drug resistance in HIV-1-infected children in the United Kingdom from 1998 to 2004. Pediatr Infect Dis J 2008; 27:457-9.
30. Foster C, Lyall H. HIV and mitochondrial toxicity in children. J Antimicrob Chemother 2008; 61:8-12.
31. European Paediatric Lipodystrophy Group. Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV infected children in Europe. AIDS 2004; 18:1443-51.
32. Mallal S, Phillips E, Carosi G, et al. HLAB*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358:568-79.
33. The Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. July, 2008. See http://aidsinfo.nih.gov/contentfiles/ PediatricGuidelines.pdf (accessed 29 October 2008].
34. Barreiro P, Soriano V. Suboptimal CD4 gains in HIV infected children receiving didanosine plus tenofovir. J Antimicrob Chemother 2006; 57:806-9.
35. Riordan A, Judd A, Boyd K, et al. Tenofovir use in HIV-1 infected children in the United Kingdom and Ireland. Pediatr Infect Dis J 2008 (in press).
36. Rodriguez-Novoa S. Barreiro P, Rendón A, et al. Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. Clin Infect Dis 2005; 40:1358-61.
37. Li AM. Ritonavir and fluticasone: beware of this potentially fatal combination. J Pediatr 2006; 148:294-5.
38. European Medicines Agency. Studies assessed by the EMEA indicate no increased risk of developing cancer for patients who have taken Viracept contaminated with ethyl mesylate (24 July 2008]. See http://www.emea.europa.eu/ humandocs/PDFs/EPAR/Viracept/38225608en.pdf (accessed 29 October 2008).
39. European Medicines Agency. European Medicines Agency recommends lifting of suspension of Viracept (20 September 2007). See http:/Avww.emea. europa.eu/pdfs/general/direct/pr/41816807en.pdf (accessed 29 October 2008).
40. de Ruiter A, Mercey D, Anderson J, et al. British HIV Association and Children's HIV Association guidelines for the management of HIV infection in pregnant women 2008. HIV Med 2008; 9:452-502
41. Food and Drug Administration. FDA HIV/AIDS List Serve Archive. Bristol-Myers Squibb Company has issued a Dear Health Care Provider Letter highlighting important information about Sustiva and pregnancy. See http://www.fda.gov/oashi/aids/Iistserve/listserve2005.html#ustiva (accessed 29 October 2008).
42. Townsend CL, Cortina-Borja M, Peckham CS, et al. Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the UK and Ireland. AIDS 2007; 21:384-6.
43. Gianquinto C, Rampon O, Torresan S, et al. Lactic acid levels in infants exposed to ART during fetal life. Abstract 941. 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, 8-11 February 2004.
44. Landreau-Mascaro A, Barret B, Mayaux MJ, et al. Risk of early febrile seizure with perinatal exposure to nucleoside analogues. Lancet 2002; 359:583-4.
45. Day E, Buckberry K, Sharland MR, et al. Novel treatment options for paediatric HIV infection. Curr Opin Investig Drugs 2008; 9:170-5.
46. Madruga JV, Berger D, McMurchie M, et al. Efficacy and safety of darunavirritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatmentexperienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet 2007; 370:49-58.
47. Harries AD, The Malawi Paediatric Antiretroviral Group. Antiretroviral therapy for children in the routine setting in Malawi. Trans R Soc Trop Med Hyg 2007; 101:511-16.
48. Lockman S, Shapiro R, Smeaton L. et al. Response to antiretroviral therapy after a single, peripartum dose of nevaripine. N Engl J Med 2007; 356:135-47.
49. McCoy D, Chopra M, Loewenson R, et al. Expanding access to antiretroviral therapy in sub-Saharan Africa: avoiding the pitfalls and dangers, capitalizing on the opportunities. Am J Public Health 2005; 95:18-22.